Eli Lilly's Oral Mounjaro Approved by FDA... Obesity Drug Competition Enters Round Two
Competition Heats Up in Oral Obesity Drug Market With FDA Approval
Lilly Highlights Dosing Convenience, While Novo Expands Its Formulations
Injectables Show Greater Efficacy, but Oral Medications Poised to Grow the Market
The U.S. Food and Drug Administration (FDA) has approved Eli Lilly's oral obesity treatment, ushering in a new phase of competition in the global obesity drug market. The market, previously dominated by injectable medications, is now expected to undergo significant changes as the focus expands to include oral medications.
On April 1 (local time), the FDA announced the approval of the oral GLP-1 (glucagon-like peptide-1) receptor agonist "Zepbound" (ingredient name: orforglipron).
Zepbound is used in combination with diet and exercise to treat obese adults or overweight adults with weight-related comorbidities. It is taken once daily in pill form and will be launched in the U.S. market in early April. A representative from Eli Lilly Korea stated, "We are currently discussing a domestic launch, but the specific timeline and plans will be determined in the future."
In clinical trials, Zepbound showed a somewhat lower weight loss effect compared to the injectable obesity drug Mounjaro (ingredient name: tirzepatide). The highest dosage group saw an average weight reduction of over 12%, with an overall weight loss of about 12–15% observed across trials. In contrast, clinical trials for the previously released Mounjaro showed a weight loss rate of over 20%.
With the launch of Zepbound, competition between Novo Nordisk and Eli Lilly, the leading players in the obesity medication market, is expected to intensify. Earlier this year, Novo Nordisk secured a lead in the market by launching the oral GLP-1 drug "Wegovy Pill" in the United States. Now, with Eli Lilly entering the market as a latecomer through Zepbound, the dominance of a single player in the oral obesity medication segment is expected to change.
Zepbound and Wegovy Pill differ in dosing methods and formulation technology. Zepbound can be taken regardless of food intake, offering greater convenience for patients. In contrast, Wegovy Pill must be taken on an empty stomach due to differences in drug structure and absorption mechanisms.
Wegovy Pill uses semaglutide, the same active ingredient as the injectable form of Wegovy. To address the limitation of peptide drugs being easily degraded in the stomach, an absorption enhancer (SNAC) is included. Zepbound, however, is a non-peptide small molecule GLP-1 receptor agonist, designed from the outset for oral administration, allowing for absorption in the body without specific intake conditions.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Industry experts believe that the successive launches of oral obesity treatments will help expand the overall market. Currently, less than 10% of eligible GLP-1 therapy candidates are actually receiving treatment. Major barriers have been identified as aversion to injections and issues with accessibility.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.